Basic79and79Clinical79Pharmacology7914th79Edition79Katzung79Trevor79Test79Bank
FULL79TESTBANK
RRRRRRINSTANT79DOWNLOAD!!
,Basic79and79Clinical79Pharmacology7914th79Edition79Katzung79Trevor79Test7 9 Ba
nk
Chapter791.79Introduction:79The79Nature79of79Drugs79&79Drug79Development79&79Regulation
1.
A79nurse79working79in79radiology79administers79iodine79to79a79patient79who7
9is79having79a79computed79tomography79(CT)79scan.79The79nurse79working79on
79the79oncology79unit79administers79chemotherapy79to79patients79who79have79c
ancer.79At79the79Public79Health79Department,79a79nurse79administers79a79measl
es-mumps-rubella79(MMR)79vaccine79to79a7914-month-
old79child79as79a79routine79immunization.79Which79branch79of79pharmacology7
9best79describes79the79actions79of79all79three7 9 nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacology79is79the79study79of79the79biologic79effects79of79chemicals.79Nurs
es79are79involved79with79clinical79pharmacology79or79pharmacotherapeutics,79
which79is79a79branch79of79pharmacology79that79deals79with79the79uses79of79dru
gs79to79treat,79prevent,79and79diagnose79disease.79The79radiology79nurse79is79ad
ministering79a79drug79to79help79diagnose79a79disease.79The79oncology79nurse79i
s79administering79a79drug79to79help79treat79a79disease.79Pharmacoeconomics79in
cludes79any79costs79involved79in79drug79therapy.
Pharmacodynamics79involves79how79a79drug79affects79the79body79and79pharmac
okinetics79is79how79the79body79acts79on79the79body.
,2.
A79physician79has79ordered79intramuscular79(IM)79injections79of79morphine
,79a79narcotic,79every79479hours79as79needed79for79pain79in79a79motor79vehicle79a
ccident79victim.79The79nurse79is79aware79this79drug79has79a79high79abuse79poten
tial.79Under79what79category79would79morphine79be79classified?
A) Schedule79I
B) Schedule79II
C) Schedule79III
D) Schedule79IV
Ans: B
Feedback:
Narcotics79with79a79high79abuse79potential79are79classified79as79Schedule79II79
drugs79because79of79severe79dependence79liability.79Schedule79I79drugs79have
79high79abuse79potential79and79no79accepted79medical79use.79Schedule79III79dr
ugs79have79a79lesser79abuse79potential79than79II79and79an79accepted79medical79
use.79Schedule79IV79drugs79have79low79abuse79potential79and79limited79depen
dence79liability.
3.
When79involved79in79phase79III79drug79evaluation79studies,79what79respo
nsibilities79would79the79nurse79have?
A) Working79with79animals79who79are79given79experimental7 9 drugs
B) Choosing79appropriate79patients79to79be79involved79in79the79drug7 9 study
C) Monitoring79and79observing79patients79closely79for79adverse7 9 effects
D) Conducting79research79to79determine79effectiveness79of79the7 9 drug
Ans: C
Feedback:
, Phase79III79studies79involve79use79of79a79drug79in79a79vast79clinical79population7
9in79which79patients79are79asked79to79record79any79symptoms79they79experienc
e79while79taking79the79drugs.79Nurses79may79be79responsible79for79helping79co
llect79and79analyze79the79information79to79be79shared79with79the79Food79and79D
rug79Administration79(FDA)79but79would79not79conduct79research79independe
ntly79because79nurses79do79not79prescribe79medications.79Use79of79animals79in
79drug79testing79is79done79in79the79preclinical79trials.79Select79patients79who79a
re79involved79in79phase79II79studies79to79participate79in79studies79where79the79p
articipants79have79the79disease79the79drug79is79intended79to79treat.79These79pati
ents79are79monitored79closely79for79drug79action79and79adverse79effects.79Phas
e79I79studies79involve79healthy79human79volunteers79who79are79usually79paid79
for79their79participation.79Nurses79may79observe79for79adverse79effects79and79t
oxicity.
4.
What79concept79is79considered79when79generic79drugs79are79substituted7
9for79brand79name79drugs?
A) Bioavailability
B) Critical79concentration
C) Distribution
D) Half-life
Ans: A
Feedback:
Bioavailability79is79the79portion79of79a79dose79of79a79drug79that79reaches79the79
systemic79circulation79and79is79available79to79act79on79body79cells.79Binders79
used79in79a79generic79drug79may79not79be79the79same79as79those79used79in79the
79brand79name79drug.79Therefore,79the79way79the79body79breaks79down79and79
uses79the79drug79may79differ,79which79may79eliminate79a79generic79drug79subs
titution.79Critical79concentration79is79the79amount79of79a79drug79that79is79neede
d79to79cause79a79therapeutic79effect79and79should79not79differ79between79gener
ic79and79brand79name79medications.79Distribution79is79the79phase79of79pharm
acokinetics,79which79involves79the79movement79of79a79drug79to79the79bodys79t
issues79and79is79the79same79in79generic79and79brand79name79drugs.79A79drugs79
half-
life79is79the79time79it79takes79for79the79amount79of79drug79to79decrease79to79hal
f79the79peak79level,79which79should79not79change79when79substituting79a79gen
eric7 9 medication.
FULL79TESTBANK
RRRRRRINSTANT79DOWNLOAD!!
,Basic79and79Clinical79Pharmacology7914th79Edition79Katzung79Trevor79Test7 9 Ba
nk
Chapter791.79Introduction:79The79Nature79of79Drugs79&79Drug79Development79&79Regulation
1.
A79nurse79working79in79radiology79administers79iodine79to79a79patient79who7
9is79having79a79computed79tomography79(CT)79scan.79The79nurse79working79on
79the79oncology79unit79administers79chemotherapy79to79patients79who79have79c
ancer.79At79the79Public79Health79Department,79a79nurse79administers79a79measl
es-mumps-rubella79(MMR)79vaccine79to79a7914-month-
old79child79as79a79routine79immunization.79Which79branch79of79pharmacology7
9best79describes79the79actions79of79all79three7 9 nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacology79is79the79study79of79the79biologic79effects79of79chemicals.79Nurs
es79are79involved79with79clinical79pharmacology79or79pharmacotherapeutics,79
which79is79a79branch79of79pharmacology79that79deals79with79the79uses79of79dru
gs79to79treat,79prevent,79and79diagnose79disease.79The79radiology79nurse79is79ad
ministering79a79drug79to79help79diagnose79a79disease.79The79oncology79nurse79i
s79administering79a79drug79to79help79treat79a79disease.79Pharmacoeconomics79in
cludes79any79costs79involved79in79drug79therapy.
Pharmacodynamics79involves79how79a79drug79affects79the79body79and79pharmac
okinetics79is79how79the79body79acts79on79the79body.
,2.
A79physician79has79ordered79intramuscular79(IM)79injections79of79morphine
,79a79narcotic,79every79479hours79as79needed79for79pain79in79a79motor79vehicle79a
ccident79victim.79The79nurse79is79aware79this79drug79has79a79high79abuse79poten
tial.79Under79what79category79would79morphine79be79classified?
A) Schedule79I
B) Schedule79II
C) Schedule79III
D) Schedule79IV
Ans: B
Feedback:
Narcotics79with79a79high79abuse79potential79are79classified79as79Schedule79II79
drugs79because79of79severe79dependence79liability.79Schedule79I79drugs79have
79high79abuse79potential79and79no79accepted79medical79use.79Schedule79III79dr
ugs79have79a79lesser79abuse79potential79than79II79and79an79accepted79medical79
use.79Schedule79IV79drugs79have79low79abuse79potential79and79limited79depen
dence79liability.
3.
When79involved79in79phase79III79drug79evaluation79studies,79what79respo
nsibilities79would79the79nurse79have?
A) Working79with79animals79who79are79given79experimental7 9 drugs
B) Choosing79appropriate79patients79to79be79involved79in79the79drug7 9 study
C) Monitoring79and79observing79patients79closely79for79adverse7 9 effects
D) Conducting79research79to79determine79effectiveness79of79the7 9 drug
Ans: C
Feedback:
, Phase79III79studies79involve79use79of79a79drug79in79a79vast79clinical79population7
9in79which79patients79are79asked79to79record79any79symptoms79they79experienc
e79while79taking79the79drugs.79Nurses79may79be79responsible79for79helping79co
llect79and79analyze79the79information79to79be79shared79with79the79Food79and79D
rug79Administration79(FDA)79but79would79not79conduct79research79independe
ntly79because79nurses79do79not79prescribe79medications.79Use79of79animals79in
79drug79testing79is79done79in79the79preclinical79trials.79Select79patients79who79a
re79involved79in79phase79II79studies79to79participate79in79studies79where79the79p
articipants79have79the79disease79the79drug79is79intended79to79treat.79These79pati
ents79are79monitored79closely79for79drug79action79and79adverse79effects.79Phas
e79I79studies79involve79healthy79human79volunteers79who79are79usually79paid79
for79their79participation.79Nurses79may79observe79for79adverse79effects79and79t
oxicity.
4.
What79concept79is79considered79when79generic79drugs79are79substituted7
9for79brand79name79drugs?
A) Bioavailability
B) Critical79concentration
C) Distribution
D) Half-life
Ans: A
Feedback:
Bioavailability79is79the79portion79of79a79dose79of79a79drug79that79reaches79the79
systemic79circulation79and79is79available79to79act79on79body79cells.79Binders79
used79in79a79generic79drug79may79not79be79the79same79as79those79used79in79the
79brand79name79drug.79Therefore,79the79way79the79body79breaks79down79and79
uses79the79drug79may79differ,79which79may79eliminate79a79generic79drug79subs
titution.79Critical79concentration79is79the79amount79of79a79drug79that79is79neede
d79to79cause79a79therapeutic79effect79and79should79not79differ79between79gener
ic79and79brand79name79medications.79Distribution79is79the79phase79of79pharm
acokinetics,79which79involves79the79movement79of79a79drug79to79the79bodys79t
issues79and79is79the79same79in79generic79and79brand79name79drugs.79A79drugs79
half-
life79is79the79time79it79takes79for79the79amount79of79drug79to79decrease79to79hal
f79the79peak79level,79which79should79not79change79when79substituting79a79gen
eric7 9 medication.
